Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Arena Pharmaceuticals, Inc.
Type
Public (NASDAQ: ARNA)
Industry Biotechnology
Founded 1997
Headquarters San Diego, California, U.S.
Key people

Jack Lief, cofounder
Dominic Behan, co-founder and senior scientist
Amit Munshi, CEO
Kevin Lind, CFO
Products Belviq
Revenue IncreaseUS$27,600,000 (FY 2012)
Operating income
DecreaseUS$−57,000,000 (FY 2012)
Net income
DecreaseUS$−85,500,000 (FY 2012)
Total assets IncreaseUS$261,000,000 (FY 2012)
Total equity IncreaseUS$98,600,000 (FY 2012)
Website www.arenapharm.com

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Arena Pharmaceuticals Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting GPCRs and other classes of receptors to. CART was used to identify drug leads able to act as receptor inhibitors to decrease a biological response or act as receptor activators to increase a biological response.

The company has one drug on the market, Belviq (lorcaserin), a weight-loss medication. The U.S. Food and Drug Administration (FDA) approved lorcaserin on June 27, 2012. The company commtitted to a sales force commitment of 200. Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. However, sales of Belviq were disappointing. In 2015 the company laid off 80 workers; this was followed in July 2016 by the layoff of another 100 employees (approximately 73% of remaining workforce). In January 2017 Arena announced that it is selling Belviq to its Japanese partner, Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty on global sales.

The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company's pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension. As of September 2014, potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmorary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin.

Investment goal date:
Dividends reinvested
Arena Pharmaceuticals, Inc. ARNA report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-09
--
--
Q4 2017
2018-03-12
--
--
Q4 2017
2018-03-06
--
--
Q3 2017
2017-11-07
0.0000
-0.8600
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-07
-0.7700
-0.7700
Q1 2017
2017-05-09
-0.9000
-0.9000
Q4 2016
2017-03-14
1.6000
1.6000
Q3 2016
2016-11-07
-0.5000
-0.5000
Q2 2016
2016-08-08
-1.1000
-1.1000
Q1 2016
2016-05-09
-0.9000
-0.9000
Q4 2015
2016-02-29
-1.1000
-1.3000
Q3 2015
2015-11-09
-1.1000
-1.1000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
1181899
BlackRock Fund Advisors
11227729
BlackRock Inc.
20032353
BlackRock Institutional Trust Company, N.A.
6238891
Camber Capital Management LLC
4250000
GEODE CAPITAL MANAGEMENT, LLC
1876137
NORTHERN TRUST CORP
2983729
OXFORD ASSET MANAGEMENT
1081912
PANAGORA ASSET MANAGEMENT INC
1216824
RENAISSANCE TECHNOLOGIES LLC
8479445
SCHWAB CHARLES INVESTMENT MANAGEMENT INC
1078955
SENZAR ASSET MANAGEMENT, LLC
1952891
STATE STREET CORP
6501791
Vanguard Group, Inc
19905389
WELLINGTON MANAGEMENT CO LLP
23583115
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BEHAN DOMINIC P
0.2300% (508000)
ARNA /
LIEF JACK
0.2800% (622189)
ARNA / MSTX /
HOFFMAN ROBERT
0.0300% (58074)
ARNA / CBMX / HRTX / TELK /
SPECTOR STEVEN W
0.0600% (128039)
ARNA /
WOODS RANDALL E
0.0400% (85257)
ARNA /
HIXSON HARRY F JR
0.0700% (148405)
ARNA / SQNM /
SHANAHAN WILLIAM R JR
0.0200% (50000)
ANTH / ARNA /
SCHNEIDER PHILLIP M
0.0400% (94257)
ARNA / ASPX /
BELCHER DONALD D
0.0600% (134257)
ARNA /
BICE SCOTT H
0.0400% (89157)
ARNA /
Nova Tina Susan
0.0400% (84257)
ADMP / ARNA / NSTG / VCYT /
White Christine Anna
0.0400% (85529)
ARNA / MEIP /
Audet Craig Michael
0.0200% (50000)
ARNA /
% ()